119 related articles for article (PubMed ID: 37778965)
1. Corrigendum to "Plasma levels of 12 different cytokines correlate to PD-1 inhibitor combined chemotherapy responses in advanced non-small-cell lung cancer patient" [Int. Immunopharmacol. 124(Part A) (2023) 110888].
Peng Y; Qi Q; Zhu M; Zhang Y; Bao Y; Liu Y
Int Immunopharmacol; 2023 Nov; 124(Pt A):110976. PubMed ID: 37778965
[No Abstract] [Full Text] [Related]
2. Plasma levels of 12 different cytokines correlate to PD-1 inhibitor combined chemotherapy responses in advanced non-small-cell lung cancer patient.
Peng Y; Qi Q; Zhu M; Zhang Y; Bao Y; Liu Y
Int Immunopharmacol; 2023 Nov; 124(Pt A):110888. PubMed ID: 37690239
[TBL] [Abstract][Full Text] [Related]
3. Corrigendum to "Exosomal circRNA-001264 promotes AML immunosuppression through induction of M2-like macrophages and PD-L1 overexpression" [Int. Immunopharmacol. 124(Part A) (2023) 110868].
Du A; Yang Q; Sun X; Zhao Q
Int Immunopharmacol; 2024 Feb; 128():111442. PubMed ID: 38185544
[No Abstract] [Full Text] [Related]
4. Corrigendum to "Transcatheter arterial chemoembolisation combined with lenvatinib and cabozantinib in the treatment of advanced hepatocellular carcinoma" [Int. Immunopharmacol. 130 (2024) 111510].
Liu H; Gan XM; Sun JM; Yang Q; Zhang DZ; Zuo Y; Liu FL; Li B; Tan QL; Zhang J
Int Immunopharmacol; 2024 Jun; ():112494. PubMed ID: 38902130
[No Abstract] [Full Text] [Related]
5. Corrigendum to "Pseudomonas aeruginosa-mannose sensitive hemagglutinin injection treated cytokine-induced killer cells combined with chemotherapy in the treatment of malignancies" [Int. Immunopharmacol. 51 (2017) 57-65].
Zhang C; Zhang Z; Wang L; Han J; Li F; Shen C; Li H; Huang L; Zhao X; Yue D; Huang J; Yan Y; Zhang Y
Int Immunopharmacol; 2022 Jan; 102():108356. PubMed ID: 34794888
[No Abstract] [Full Text] [Related]
6. Retraction notice to "Corrigendum to "MLL1 promotes migration and invasion of fibroblast-like synoviocytes in rheumatoid arthritis by activating the TRIF/NF-κB signaling pathway via H3K4me3 enrichment in the TLR4 promoter region"" [Int. Immunopharmacol. 82 (2020) 106220] [Int. Immunopharmacol. 92 (2021) 107321].
Zhang Y; Ji T; Ma S; Wu W
Int Immunopharmacol; 2023 Apr; 117():109865. PubMed ID: 36822094
[No Abstract] [Full Text] [Related]
7. Corrigendum to "PAD4 selective inhibitor TDFA protects lipopolysaccharide-induced acute lung injury by modulating nuclear p65 localization in epithelial cells" [Int. Immunopharmacol. 88 (2020) 106923].
Zhao X; Gu C; Wang Y
Int Immunopharmacol; 2023 Dec; 125(Pt B):111185. PubMed ID: 37957096
[No Abstract] [Full Text] [Related]
8. Corrigendum to "Berberine regulates PADI4-related macrophage function to prevent lung cancer" [Int. Immunopharmacol. 110 (2022) 108965].
Gu W; Zhang M; Gao F; Niu Y; Sun L; Xia H; Li W; Zhang Y; Guo Z; Du G
Int Immunopharmacol; 2023 Jul; 120():110366. PubMed ID: 37258402
[No Abstract] [Full Text] [Related]
9. Corrigendum to "STA-21, a small molecule STAT3 inhibitor, ameliorates experimental autoimmune encephalomyelitis by altering Th-17/Treg balance" [Int. Immunopharmacol. 119 (2023) 110160].
Gharibi T; Barpour N; Hosseini A; Mohammadzadeh A; Marofi F; Ebrahimi-Kalan A; Nejati-Koshki K; Abdollahpour-Alitappeh M; Safaei S; Baghbani E; Baradaran B
Int Immunopharmacol; 2023 Jun; 119():110303. PubMed ID: 37179201
[No Abstract] [Full Text] [Related]
10. Corrigendum to "1,2-diacetylbenzene impaired hippocampal memory by activating proinflammatory cytokines and upregulating the prolactin pathway: An in vivo and in vitro study" [Int. Immunopharmacol. 108 (2022) 108901].
Nguyen HD; Jo WH; Hoang NHM; Yu BP; Chung HY; Kim MS
Int Immunopharmacol; 2022 Oct; 111():109156. PubMed ID: 35995727
[No Abstract] [Full Text] [Related]
11. Corrigendum to "(E)-2-methoxy-4-(3-(4-methoxyphenyl)prop-1-en-1-yl)phenol alleviates inflammatory responses in LPS-induced mice liver sepsis through inhibition of STAT3 phosphorylation" [Int. Immunopharmacol. 125(Part B) (2023) 111124].
Kim B; Yu JE; Yeo IJ; Son DJ; Lee HP; Roh YS; Lim KH; Yun J; Park H; Han SB; Hong JT
Int Immunopharmacol; 2024 Jun; ():112543. PubMed ID: 38926074
[No Abstract] [Full Text] [Related]
12. Corrigendum to "Emodin attenuates acute lung injury in cecal-ligation and puncture rats" [Int. Immunopharmacol. 85 (2020) 106626].
Guo R; Li Y; Han M; Liu J; Sun Y
Int Immunopharmacol; 2023 Sep; 122():110700. PubMed ID: 37507324
[No Abstract] [Full Text] [Related]
13. Corrigendum to "Inhibition of MRP4 alleviates sepsis-induced acute lung injury in rats" [Int. Immunopharmacol. 72 (2019) 211-217].
Xia W; Zhang H; Pan Z; Li G; Zhou Q; Hu D; Liu Y
Int Immunopharmacol; 2023 Sep; 122():110699. PubMed ID: 37500384
[No Abstract] [Full Text] [Related]
14. Corrigendum to "MEGF6 prevents sepsis-induced acute lung injury in mice" [Int. Immunopharmacol. 123 (2023) 110727].
Liang H; Liu G; Zeng W; Fan Q; Nie Z; Hu H; Zhang R; Xie S
Int Immunopharmacol; 2024 May; 133():111787. PubMed ID: 38641473
[No Abstract] [Full Text] [Related]
15. Immune-related adverse events of a PD-L1 inhibitor plus chemotherapy versus a PD-L1 inhibitor alone in first-line treatment for advanced non-small cell lung cancer: A meta-analysis of randomized control trials.
Wang M; Liang H; Wang W; Zhao S; Cai X; Zhao Y; Li C; Cheng B; Xiong S; Li J; He J; Liang W
Cancer; 2021 Mar; 127(5):777-786. PubMed ID: 33119182
[TBL] [Abstract][Full Text] [Related]
16. Corrigendum to "Baicalin suppresses IL-1β-induced expression of inflammatory cytokines via blocking NF-κB in human osteoarthritis chondrocytes and shows protective effect in mice osteoarthritis models" [Int. Immunopharmacol. 52 (2017) 218-226].
Chen C; Zhang C; Cai L; Xie H; Hu W; Wang T; Lu D; Chen H
Int Immunopharmacol; 2021 Jun; 95():107546. PubMed ID: 33735716
[No Abstract] [Full Text] [Related]
17. Corrigendum to "Biomimetic amphiphilic FAAP NPs nanoparticles: Synthesis, characterization and antivirus activity" [Int. Immunopharmacol. 101(Part A) (2021) 108047].
Li X; Zhang Z; Ma X; Guo Z; Ban X; Tian Z; Zhao L; Liu Q; He Q
Int Immunopharmacol; 2023 Sep; 122():110735. PubMed ID: 37544813
[No Abstract] [Full Text] [Related]
18. Corrigendum to "Sophoricoside attenuates lipopolysaccharide-induced acute lung injury by activating the AMPK/Nrf2 signaling axis" [Int. Immunopharmacol. 90 (2021) 107187].
Wu YX; Zeng S; Wan BB; Wang YY; Sun HX; Liu G; Gao ZQ; Chen D; Chen YQ; Lu MD; Pang QF
Int Immunopharmacol; 2023 Nov; 124(Pt A):111008. PubMed ID: 37806791
[No Abstract] [Full Text] [Related]
19. Corrigendum to "Rapamycin regulates osteogenic differentiation through Parkin-mediated mitophagy in rheumatoid arthritis" [Int. Immunopharmacol. 113(Part B) (2022) 109407].
Chen Q; Fan K; Song G; Wang X; Zhang J; Chen H; Qin X; Lu Y; Qi W
Int Immunopharmacol; 2023 Nov; 124(Pt A):110941. PubMed ID: 37718175
[No Abstract] [Full Text] [Related]
20. Corrigendum to "Taxifolin ameliorates Benzo[a]pyrene-induced lung injury possibly via stimulating the Nrf2 signalling pathway" [Int. Immunopharmacol. 96 (2021) 107566].
Islam J; Shree A; Vafa A; Afzal SM; Sultana S
Int Immunopharmacol; 2023 Jun; 119():110096. PubMed ID: 37095029
[No Abstract] [Full Text] [Related]
[Next] [New Search]
